Tag: #Orforglipron
-

Eli Lilly’s Major Netherlands Plant Investment: Scaling Supply for Oral Obesity Therapy
On November 4, 2025, Eli Lilly and Company announced a multi-billion-dollar investment in a new manufacturing facility in the Netherlands to support global rollout of its oral obesity drug orforglipron and fortify its trans-Atlantic production network.